arrow_back Back

CleanCap® M6 EGFP ModTail™ mRNA (N1MePsU)

SKU: L-8101A

Description

This mRNA construct, produced via in vitro transcription (IVT), expresses an enhanced version of the green fluorescent protein (EGFP), originally isolated from the jellyfish Aequorea victoria. EGFP is a commonly used direct detection reporter in mammalian cells, yielding bright green fluorescence with an emission peak at 509 nm.

Key features of this mRNA construct to maximize protein expression include:

  • Resembles mature mRNA — containing a CleanCap® cap analog, 5′ and 3′ UTRs, a coding sequence, and a 120-nt poly(A) tail — for efficient ribosomal translation
  • Capped with CleanCap® Reagent M6 for up to ≥30% higher protein expression compared to enzymatic caps and previous CleanCap AG analogs
  • Poly(A) tail modified with TriLink’s proprietary ModTail™ technology for increased protein expression and duration
  • Incorporates N1-methylpseudouridines in place of uridines for reduced inflammatory responses and increased protein expression

Product details
Catalog No L-8101A
Purity Passes Agarose Gel Mobility
Concentration 1.0 mg/mL
Buffer 1 mM Sodium Citrate pH 6.4
Recommended Storage At or below -40°C
Application Reporter Genes
Base Composition Fully substituted with N1-Methyl-Pseudo-U
Brand CleanCap
Cap AG Start
Cap Analogs CleanCap M6
Composition Fully substituted with N1-Methyl-Pseudo-U, ModTail technology
Conversion Factor 40 µg/OD₂₆₀
length 997 nucleotides
Product Grade RUO
Shipping Temp Frozen

Technical documents

Product FAQs

Our catalog mRNAs are intended for research use and manufactured with procedures in place to minimize endotoxin exposure. However, they are manufactured outside of a cleanroom and thus are not released with an endotoxin specification. †If you need mRNA released with an endotoxin specification or a higher grade of material, please contact mmrna-services@trilinkbiotech.com.

The sequence reported is just the ORF, start codon to stop codon, for our catalog mRNAs. It does not include the proprietary 5_ UTR, 3_ UTR, or the 120-nt poly-A tail. For full mRNA length and the length of the ORF please see the corresponding product insert.

Our catalog mRNAs are purified through DNase treatment to remove DNA templates, diafiltration to remove salts and small molecules, and oligo dT capture to remove impurities and retain species with poly(A) tails.

We use 40 as the extinction coefficient for our mRNAs. Assigning a sequence-specific extinction coefficient for mRNA can be problematic due to its dependence on length and sequence composition.  Factors like final buffer and temperature can also impact results.  Thus, it is standard to use 40 for all mRNA species and not to calculate a coefficient for each sequence as you would with an oligonucleotide.

TriLink’s ModTail™ technology is our proprietary poly(A) modification of mRNA. It involves a single small chemical moiety linked to the 3′-end of the poly(A) tail of mRNA after the in vitro transcription reaction.  There are no other changes to the mRNA.

TriLink’s ModTail™ mRNAs should be compatible with commonly used delivery vehicles. We have used it with common transfection reagents and LNPs, including LipofectamineTM MessengerMAXTM reagents, and ALC-0315, DSPC, Cholesterol, and DMG-PEG 2000: Pfizer/Acuitas Lipids.

No, we have data showing that ModTail™ mRNAs are of comparable integrity to regular oligo-dT-purified mRNAs.

How our modification increases the protein expression and duration is currently under investigation; however, we hypothesize it prevents 3′-exonucleosase cleavage as one of the mechanisms.

We have not observed meaningful differences in the immunogenicity of tail-modified mRNA from non-tail-modified mRNA in our in vitro and in vivo studies.

It is currently available through our Custom (RUO) mRNA synthesis services. You can request a quote or order through our mRNAbuilder® configuration tool.

Our research use only (RUO) terms and conditions cover research use of TriLink’s ModTail™ mRNAs. If you have additional questions, please contact sales@trilinkbiotech.com.

We recommend storing the mRNAs at -40° C to -80° C. To minimize freeze-thaw cycles, aliquot the sample into single-use quantities on the first usage. If kept under these conditions, our catalog mRNAs have been shown to maintain stability for at least 2 years.

Certificate of analysis

Intellectual property

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

CleanCap capping technology

For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patents and patent pending, see trilinkbiotech.com/legal-notices.

Mutant GFP mRNA

These products are sold with a Limited Use Label License under sublicense with Life Technologies, Inc. Please review Limited License at trilinkbiotech.com/gfp-label-license.

support Contact us home Return to TriLink homepage